Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 10;41(2):170-172.
doi: 10.1200/JCO.22.01711. Epub 2022 Oct 20.

Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy

Aaron P Mitchell  1 , Daniel A Goldstein  2   3   4   5
Affiliations
Editorial

Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy

Aaron P Mitchell et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Daniel A. Goldstein

Stock and Other Ownership Interests: TailorMed, Vivio Health

Consulting or Advisory Role: Vivio Health

Research Funding: MSD (Inst), BMS (Inst), Janssen (Inst)

No other potential conflicts of interest were reported.

Comment on

  • Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
    Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.

References

    1. Patil VM, Noronha V, Menon N, et al. : Low-dose immunotherapy in head and neck cancer: A randomized study. J Clin Oncol 41:222-232, 2023 - PubMed
    1. Ferris RL, Blumenschein G, Fayette J, et al. : Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856-1867, 2016 - PMC - PubMed
    1. Cohen EEW, Soulières D, Le Tourneau C, et al. : Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet 393:156-167, 2019 - PubMed
    1. Ratain MJ, Goldstein DA: Time is money: Optimizing the scheduling of nivolumab. J Clin Oncol 36:3074-3076, 2018 - PubMed
    1. Brahmer JR, Drake CG, Wollner I, et al. : Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010 - PMC - PubMed

Substances